Shopping Cart

Your shopping cart is currently empty

GSK2593074A

Name: GSK2593074A
Brand: TargetMol
SKU: T11484
Price: 116 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T11484Cas No. 1337531-06-2

Alias GSK'074

GSK2593074A (GSK'074) is a programmed necrosis inhibitor that displays inhibitory effects on RIP1 and RIP3.

GSK2593074A

Copy Product Info

😃Good

Purity: 99.99%

Catalog No. T11484Alias GSK'074Cas No. 1337531-06-2

GSK2593074A (GSK'074) is a programmed necrosis inhibitor that displays inhibitory effects on RIP1 and RIP3.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$116	In Stock	In Stock
5 mg	$289	In Stock	In Stock
10 mg	$455	-	In Stock
25 mg	$763	-	In Stock
50 mg	$1,070	-	In Stock
100 mg	$1,430	-	In Stock
1 mL x 10 mM (in DMSO)	$318	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.99%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	GSK2593074A (GSK'074) is a programmed necrosis inhibitor that displays inhibitory effects on RIP1 and RIP3.
In vitro	GSK2593074A (GSK'074) (0.01, 0.1, 1, 10, and 100 nM; 6 h) fully prevents necroptosis across various stimuli in both human and murine cells with IC50~3 nM, including MOVAS cells and L929 cells.[1]
In vivo	GSK2593074A (GSK'074) (0.93 mg/kg/day; i.p.; 14 or 28 days; mice) show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (36.28±5.76%; P<0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (27.36±8.25%; P<0.05). Inhibited aneurysm formation in mouse models of aneurysms.[1]
Synonyms	GSK'074

Chemical Properties

Molecular Weight	465.57
Formula	C₂₇H₂₃N₅OS
Cas No.	1337531-06-2
Smiles	Cn1cc(cn1)-c1cnc(N)c2c(csc12)-c1ccc2N(CCc2c1)C(=O)Cc1ccccc1
Relative Density.	1.39 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 41.67 mg/mL (89.5 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.3 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1479 mL	10.7395 mL	21.4790 mL	107.3952 mL
5 mM	0.4296 mL	2.1479 mL	4.2958 mL	21.4790 mL
10 mM	0.2148 mL	1.0740 mL	2.1479 mL	10.7395 mL
20 mM	0.1074 mL	0.5370 mL	1.0740 mL	5.3698 mL
50 mM	0.0430 mL	0.2148 mL	0.4296 mL	2.1479 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc